Brief: AB Science Received FDA Authorization To Resume Patient Enrollment In Masitinib Phase 3 Study
19/11/2021 07:54
Nov 19 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVED AUTHORIZATION FROM THE FDA TO RESUME
PATIENT
ENROLLMENT IN THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB
(AB19001) IN PATIENTS WITH ALS, THE CO ANNOUNCED ON THURSDAY
* STUDY AB19001 HAS NOW BEEN AUTHORIZED IN 15 COUNTRIES IN
EUROPE,
USA, AND OTHER REGIONS AND IS ACTIVELY ENROLLING PATIENTS
Source text for Eikon: ID:nGNX6scSVp
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041